Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 908-915

  Wade, Michael ^a   Hunt, Thomas L ^c   Lai, Allen A ^b  

^a UNITED THERAPEUTICS CORPORATION   (United States)

^b CPKD Solutions   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

Anticoagulation; Drug interaction; Prostacyclin analogue; Pulmonary arterial hypertension; Treprostinil; Warfarin

Indexed keywords

UNIPROST; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENANTIOMER; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; INJECTION SITE; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN EDEMA; SKIN MANIFESTATION;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPOPROSTENOL; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PLATELET AGGREGATION INHIBITORS; STEREOISOMERISM; TIME FACTORS; WARFARIN;

EID: 0038795260     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00012     Document Type: Article

References (22)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
2. McLaughlin VV, Genthner DE, Panella MM, et al. 1998. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-7.
3. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial. Ann Intern Med 2000; 132:425-34.
4. Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue disease. Thorax 1999;54:273-7.
5. Rosenzweig EB, Kerstein D, Barst RJ. Long term prostacyclin for pulmonary hypertension associated congenital heart defects. Circulation 1999; 99:1858-65.
6. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-3.
7. Higenbottam T, Stenmark K, Simonneau G. Treatments for severe pulmonary hypertension. Lancet 1999;353:338-40.
8. McLaughlin, W, Gain SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9.
9. Graham DR, Kelermans MM, Klemm LW, et al. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991;91: 95S-100S.
10. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med 2001;165:800-4.
11. Rashid A, Lehrman S, Romano P, et al. Primary pulmonary hypertension. Heart Dis 2000;2:422-30.
12. Frazier SK. Diagnosing and treating primary pulmonary hypertension. Nurse Pract 1999;24:18-26.
13. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-7.
14. Peacock AJ. Primary pulmonary hypertension. Thorax 1999;54:1107-18.
15. Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatr Clin North Am 1999;46:331-45.
16. Rich S, ed. Primary pulmonary hypertension: executive summary from the World Symposium on primary pulmonary hypertension. Available at: http://www.who.int/ncd/cvd/.pph/html. Accessed September 2002.
17. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-7.
18. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
19. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anoretic drug-induced pulmonary hypertension. Chest 1997; 112:714-21.
20. Kwan D, Bartle W, Walter S. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68-75.
21. th ed. Montvale, NJ: Medical Economics Company; 2001.
22. Verstuyft C, Morin S, Robert A, et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001;11:735-7.